Valneva SE’s (VALN) chikungunya vaccine candidate VLA1553 is under FDA review, with a decision expected by the end of August 2023.Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus. Fever, severe joint pain, joint swelling, muscle pain, headache, nausea, fatigue and rash are some of the symptoms of chikungunya. There is currently no approved vaccine or specific treatment for chikungunya virus infections.If approved, VLA1553 could become the first licensed chikungunya vaccine available to address this unmet medical need.VALN closed Friday’s (Jul.28, 2023) trading at $14.80, up 1.44%.